New Antibiotics Hailed as a 'Pivotal Moment' in Addressing Antibiotic-Resistant Gonorrhea
The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the effort against superbug strains of the infection, according to scientists.
A Global Health Concern
Gonorrhoea infections are increasing globally, with estimates suggesting over 82 million instances each year. Notably increased rates are reported in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.
“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, the spread of superbugs and the extremely scarce available drugs at this time.”
Health officials are deeply concerned about the surge in treatment-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.
Two New Treatment Options Secure Authorization
One new antibiotic, also known as a brand name, was approved by the US FDA in December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists hope that specific application of this new drug will help delay the emergence of superbugs.
Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.
An Innovative Approach to Creation
Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.
“This authorization signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”
Clinical Trial Data and Global Access
As per data published in a prominent scientific publication, the new drug cured more than 90% of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which involves an injection and a pill. The trial involved nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.
As part of the agreement of its unique model, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.
Clinicians on the front lines have shared hope. The availability of a one-pill regimen such as this is described as a "critical tool" for public health efforts. This is considered vital to alleviate the strain of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.
